Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04853342 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Study acronym: FORWARD
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Jan 2026 → Dec 2026
See other at-risk trials from Allist Pharmaceuticals, Inc.

Record History

  1. Primary completion pushed from Jan 2026 to Dec 2026v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Dec 2023 to Jan 2026
    • Study sites: 0 to 1
    • Study completion date: Jan 2025 to Jan 2030
    • Start date changed from estimate of Apr 17, 2021 to Jun 7, 2021
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients with stage II-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy.
Trial Details
NCT Number NCT04853342
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Non-small Cell Lung Carcinoma
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 318 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov